Treace Medical Q4 rev $49.8M (+49% YoY); FY rev $141.8M (+50%); FY23 guide $187-193M

TREACE MEDICAL CONCEPTS, INC.

Q4 revenue $49.8M (+49% YoY); FY2022 revenue $141.8M (+50% YoY).
Q4 net loss ($4.4M) or ($0.08)/share; Adjusted EBITDA positive $0.3M (vs loss $4.0M in Q4 2021).
FY2022 net loss ($42.8M) or ($0.77)/share; Adjusted EBITDA loss ($23.7M).
Completed follow-on offering raising net proceeds $107.5M; cash & securities $81.3M at year-end.
FY2023 revenue guidance $187-193M (32-36% growth).

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

TREACE MEDICAL CONCEPTS, INC. reported the fourth quarter ended December 31, 2022 results: revenue $49.8 million, net income ($4.4) million, or ($0.08) per share, EPS ($0.08) per share.

Period: the fourth quarter ended December 31, 2022
Revenue: $49.8 million
Net income: ($4.4) million, or ($0.08) per share
EPS: ($0.08) per share
Result: reported results

Exact text from the filing

of hallux valgus (commonly known as bunions), today reported financial results for the fourth quarter and full year ended December 31, 2022. Recent Highlights: • Revenue of $49.8 million in the fourth quarter of 2022, a 49% increase over the same period last year and a 51% increase sequentially. Full year 2022 revenue of $141.8 million increased 50% over 2021. •

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

TREACE MEDICAL CONCEPTS, INC. reported the year ended December 31, 2022 results: revenue $141.8 million, net income ($42.8) million, or ($0.77) per share, EPS ($0.77) per share.

Period: the year ended December 31, 2022
Revenue: $141.8 million
Net income: ($42.8) million, or ($0.77) per share
EPS: ($0.77) per share
Result: reported results

Exact text from the filing

Highlights: • Revenue of $49.8 million in the fourth quarter of 2022, a 49% increase over the same period last year and a 51% increase sequentially. Full year 2022 revenue of $141.8 million increased 50% over 2021. • Blended average revenue per Lapiplasty® procedure kit sold was $5,907, a 10% increase over the same period last year and a 2% increase sequentially.

View on SEC.gov

Browse all earnings releases →

TREACE MEDICAL CONCEPTS, INC. filing history →

Source: SEC EDGAR

accession 0000950170-23-006457

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.